chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Nose bleeds every 12 hours; Starting to get headaches; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 05Apr2021 at 13:00 (at the age of 22-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma as a kid. The patient had history of known allergies to cefalexin (KEFLEX). Concomitant medication included sertraline hydrochloride (ZOLOFT); from an unknown date for unknown indication. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021 at 04:00, the patient had nose bleeds in every 12 hours and started to get headaches. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of reported events. The clinical outcome of nose bleeds every 12 hours and headache was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Pt. return to clinic informed of adverse reaction to rt. arm from receiving Men-B on 2/22/2018. Nurse noted pt. arm red swollen with red rash at the injection site. Pt. stated it painful to touch.  Provider Dr. came to assess pt. Pt. state she had taken Claritin. Dr. informed pt. to continue taking the Claritin and apply cold compress when needed. Dr. informed pt. it could be a week or more for swelling to go down. Call clinic if she need further assistance.
7/15/21 presented to the office with persistent cough and hemoptysis for 9 days.
pt recvd 2 doses of Engerix-B vax & exp arthralgia following both injects; no tx was given;
Information has been received from a pharmacy student concerning a 17 year old patient who on 22-JUL-2010 was inadvertently vaccinated a dose of ZOSTAVAX (Merck) instead of VARIVAX (Merck). No adverse event was reported. No further information is available.
In order of onset: scleral hemorrhage,  scleral chemosis, lower extremity edema, acute onset labrynthitis (vertigo, tinnitus, R ear sensorineural hearing loss), joint pain, worsening hypertension.  At this time, hearing loss is permanent
2nd day: Left Arm Sore, Chills, Fever (101), joint aches all day, very tired
VOMITING; SEVERE CHILLS (UNCONTROLLABLE SHAKING); FEVER; HEADACHE; DOWN FOR 24 HOURS; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced vomiting, down for 24 hours, severe chills (uncontrollable shaking), fever, and headache. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from down for 24 hours, fever, and headache, and the outcome of vomiting and severe chills (uncontrollable shaking) was not reported. This report was non-serious.
Patient developed a dull headache and low grade fever (99.4) 10 days after recieving the MMR and Influenza vaccine. She then developed a macular, non-blanching, errythemenous rash over face and neck and then distally more scattered. Headache and low grade fever stopped after 2 days and rash continued. She was seen in the clinic 4/1/19 with the rash. In the past she only had recieved the Measles and Mumps vaccines seperately in 2005. This was also her first influenza vaccine.
Patient had rash on both arms from shoulders to forearm. She did not report any pain, just itching.
Temp 102 for 8 hrs., pain and itching in right arm, chills, night sweats, soreness and pain in joints, nausea ; aing about 36 hours
Wife reports temp of 101.4 increased BP and pulse, shaking. Still not feeling well after 8 days.
fatigue; body aches; headache; unable to breathe; feel really weak; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (unable to breathe), ASTHENIA (feel really weak), FATIGUE (fatigue), MYALGIA (body aches) and HEADACHE (headache) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-May-2021, the patient experienced DYSPNOEA (unable to breathe) and ASTHENIA (feel really weak). On an unknown date, the patient experienced FATIGUE (fatigue), MYALGIA (body aches) and HEADACHE (headache). At the time of the report, DYSPNOEA (unable to breathe), ASTHENIA (feel really weak), FATIGUE (fatigue), MYALGIA (body aches) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment information was unknown.   Reporter did not allow further contact
RASH ON SHOULDER/ARM; CHILLS; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020, expiry: UNKNOWN) dose was not reported, administered on 14-MAR-2021 for prophylactic vaccination. No concomitant medications were reported.  On 14-MAR-2021, the subject experienced rash on shoulder/arm. On 14-MAR-2021, the subject experienced chills. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills on 14-MAR-2021, and had not recovered from rash on shoulder/arm. This report was non-serious.
sore arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "recovered", described as "sore arm".  Additional information: Age of patient: 68, unit: Unknown. For the first dose, sore arm for a day and a half.   No follow-up attempts are possible. No further information is expected.
Diarrhea & felt cold, shaky, sweating, also redness and swelling around injection site. Cephalexin 500 mg QID.
Pt states that after receiving flu shot she has pain in her left arm. NKDA. Cannot lift arm above/behind head. Pt. states pain when pulling and lifting items.
This spontaneous report was received from a pharmacist referring to a patient of unknown age. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On an unknown date, the patient was vaccinated with M-M-R II, intramuscularly for prophylaxis (dose, lot number and expiration date were not reported).
Pinpoint red rash back, chest, hairline, arms, legs. Afebrile. Lack of appetite. Referred to PCP.
MULTIPLE TEMPERATURE EXCURSIONS; INCORRECTLY STORED VACCINE ADMINISTERED; OUT OF SPECIFICATION PRODUCT USE; This spontaneous report received from a health care professional concerned multiple patients. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 212A21A, expiry: UNKNOWN) dose, start therapy date were not reported for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, the patient experienced multiple temperature excursions, incorrectly stored vaccine administered, and out of specification product use. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the temperature excursion, out of specification product use and incorrectly stored vaccine administered was not reported. This report was non-serious. This case, from the same reporter is linked to 20220242461.
Husband and wife came in 4/5 and received their COVID vaccines at 11am. They waited the 15 minutes to check for reactions and were unsymptomatic when time was up. The pharmacy did a courtesy call around 3:15 pm on 4/7 to check in with them and see how they were feeling. The wife stated that her husband had passed away the night of 4/5. Wife stated that they were getting ready to go to bed and husband felt hot and shaky so he laid in front of a fan. Wife eventually had to do CPR and stated that she thinks that he passed away during the time while they were waiting for EMS, which took about 45 minutes. Patient was pronounced dead night of 4/5.  Wife stated that patient has a history of heart problems including hypertension and multiple stents place and that she does not think the vaccine had to do with her husband's death.
L arm was red and painful the day after shot was given (MMR); 2cm erythema, 1.5 cm induration, warm, tender; no streaks; no increased lymph nodes
This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE MASS (injection site formed a bump), INJECTION SITE WARMTH (injection site was hot), INJECTION SITE PRURITUS (injection site itches) and INJECTION SITE ERYTHEMA (injection site was red) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On 05-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced INJECTION SITE MASS (injection site formed a bump), INJECTION SITE WARMTH (injection site was hot), INJECTION SITE PRURITUS (injection site itches) and INJECTION SITE ERYTHEMA (injection site was red). At the time of the report, INJECTION SITE MASS (injection site formed a bump), INJECTION SITE WARMTH (injection site was hot), INJECTION SITE PRURITUS (injection site itches) and INJECTION SITE ERYTHEMA (injection site was red) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medications were not provided. Treatment information was not reported.
Developed Covid symptoms after Moderna Dose 3; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Developed Covid symptoms after Moderna Dose 3) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy.   On 18-Feb-2021 at 3:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021 at 3:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Nov-2021 at 12:00 PM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Developed Covid symptoms after Moderna Dose 3). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 09-May-2022 to 14-May-2022 for COVID-19 prophylaxis, at a dose of 1 dosage form. At the time of the report, COVID-19 (Developed Covid symptoms after Moderna Dose 3) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  Patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment.  Device Date was reported as 19May2022.  Company Comment: This spontaneous case concerns a 74-year-old, female patient with past drug history of administration of two doses of the mRNA-1273 vaccine, who experienced the unexpected, non-serious of COVID-19. The event occurred approximately 5 months after receiving the third dose of the mRNA-1273 vaccine. The patient developed COVID-19 symptoms (unspecified). She took and completed a 6-day course of Paxlovid (nirmatrelvir, ritonavir) from 09May2022 to 14May2022. It was reported that the patient again developed COVID-19 symptoms (unspecified) 5 days after treatment with Paxlovid. No additional details were provided at the time of the report. The patient's advanced age (high risk for infections) remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 74-year-old, female patient with past drug history of administration of two doses of the mRNA-1273 vaccine, who experienced the unexpected, non-serious of COVID-19. The event occurred approximately 5 months after receiving the third dose of the mRNA-1273 vaccine. The patient developed COVID-19 symptoms (unspecified). She took and completed a 6-day course of Paxlovid (nirmatrelvir, ritonavir) from 09May2022 to 14May2022. It was reported that the patient again developed COVID-19 symptoms (unspecified) 5 days after treatment with Paxlovid. No additional details were provided at the time of the report. The patient's advanced age (high risk for infections) remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.
Fecal and urinary incontinence, extreme confusion, disorientation, severe "brain fog", difficulty walking requiring assistance,  inability to get our of bed without assistance, minimal  response to questions or commands.  She did have some "brain fog" the day after her 2nd shot with Madurna 7 months before,  but this was much more severe following this 3rd (booster) shot. Lasted all day, but resolved by next morning.
Headache, Myalgia, NauseaVomiting, CHILLS Narrative:
Experienced rash, bumps, flushing, headache.  Symptoms started one hour after vaccination.  Treatment included benadryl IV, solumedrol IV.  Left work to go home after being seen in the ED.
This case involves a patient (demographics unknown) who experienced influenza B (influenza), sniffling (rhinorrhoea), shingles (herpes zoster) and one small blister (blister) after receiving INFLUENZA VACCINE and VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX)  It was unknown if the patient had any medical history, concomitant disease or risk factor.  The patient's medical treatment(s), past vaccination(s), concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date was not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect SHINGRIX not produced by Sanofi Pasteur lot number not reported via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious influenza B (influenza), sniffling (rhinorrhoea), shingles (herpes zoster) and one small blister (blister) (unknown latency) following the administration of INFLUENZA VACCINE.  It was reported "I have had very mild breakthrough after flu and shingles shots. In both cases I had no symptoms. I was sniffling and thought it was allergy until a nasal swab revealed Influenza B. A routine visit to the dermatologist revealed one small blister which he diagnosed as shingles. All I can say is thank God I got the shots".  It was unknown if the patient experienced any additional symptoms/events.  Relevant laboratory test results included:  On an unknown date, nasopharyngeal swab (culture throat) of the patient was done and revealed Influenza B.  It was not reported if the patient received any corrective treatment for the events.  The reporter did not report causality of events with suspect.  At time of reporting, the outcome of events was unknown.  There will be information available on the batch number for this case.
Broke out with rash and hives 4-7-07 x 3 days.
Headache, Myalgia, Fever, chills, "bone aches" Narrative:
I was a little sick from the chest with cough; Cough; This is a spontaneous report from a contactable consumer or other non hcp. A patient of unspecified age and gender received first dose of bnt162b2 (BNT162B2, solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as SINGLE for covid-19 immunization. The patient medical history and concomitant medications were not reported. During the call the patient stated, who got the first dose of the pfizer vaccine and they told to wait two weeks. But to get the second dose, but it turns out that when went to get the second dose the patient was a little sick from the chest with cough (occurred on 12Feb2021). The nurse told to wait, to consult with the doctor to see if could put it back on, and felt better today who went to put it on the second dose but there was nothing, and everyone has left here. The outcome of events was recovering.    Follow-up attempts completed. No further information expected.
scratchy throat, weakness, fever (103), chills, uncontrollable shaking, body aches, dizziness, nausea
patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent; No adverse Event; This spontaneous case was reported by a nurse and describes the occurrence of UNDERDOSE (patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse Event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced UNDERDOSE (patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse Event). At the time of the report, UNDERDOSE (patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse Event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse Event) to be not related. No further causality assessment was provided for UNDERDOSE (patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent).    No concomitant drug information was provided. It was unknown if the patient had received any other vaccine 4 weeks prior to COVID-19 vaccine. No treatment drug information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Live follow-up included narrative updated.
Pt came up to medical staff in observation room after waiting 15 minutes. Pt stated she felt heart palpitations. This RN brought her and her son back to the resting area and started collecting information. Upon auscultation, pt's heart rate was 86. The first BP collected was 168/89. After talking to the pt, she stated she was "nervous". This RN guided her in some deep breathing, calming conversation, and gave her some water. After five minutes, this RN rechecked her vitals and her heart rate was 82 and blood pressure was 136/85. Pt stated she was feeling better. Her son stated she would rest at his house for a couple hours. This RN directed them to contact her PCP if she were to have further concerns.
I started to have sever migraines on June 1st and was later diagnosed with an olfactory dysfunction.
Right arm swelled from shoulder to wrist; also went into right side of face up to the right eye (numb/lazy feeling).  Brought to allergist at hospital.  Given Benadryl shot and presnidsone.  Swelling went down after two days.
Hot & Cold Feeling; Sweating; Fever 102 F; Swollen Lymph nodes Armpit; Joint Pain; Stomach hurt Severely; Could not get out of bed; This spontaneous case was reported by an other health care professional and describes the occurrence of FEELING OF BODY TEMPERATURE CHANGE (Hot & Cold Feeling), HYPERHIDROSIS (Sweating), PYREXIA (Fever 102 F), LYMPHADENOPATHY (Swollen Lymph nodes Armpit) and ARTHRALGIA (Joint Pain) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022M20A and 004M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced FEELING OF BODY TEMPERATURE CHANGE (Hot & Cold Feeling), HYPERHIDROSIS (Sweating), PYREXIA (Fever 102 F), LYMPHADENOPATHY (Swollen Lymph nodes Armpit), ARTHRALGIA (Joint Pain), ABDOMINAL PAIN UPPER (Stomach hurt Severely) and BED REST (Could not get out of bed). At the time of the report, FEELING OF BODY TEMPERATURE CHANGE (Hot & Cold Feeling), HYPERHIDROSIS (Sweating), PYREXIA (Fever 102 F), LYMPHADENOPATHY (Swollen Lymph nodes Armpit), ARTHRALGIA (Joint Pain), ABDOMINAL PAIN UPPER (Stomach hurt Severely) and BED REST (Could not get out of bed) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not provided by the reporter.  The treatment medication was Unknown.   This case was linked to MOD-2021-066952 (Patient Link).
Tuesday (21MAY2019) the patient reported that he was in good health, with no medical issues or concerns and received the smallpox vaccination 15 jabs to his right shoulder at roughly 09:00am. Roughly two hours later by report of the patient he began experiencing difficulty breathing with shortness of breath and generalized muscle weakness and then drove himself to the hospital to be evaluated. From the hospital emergency dept. the patient was admitted to the intensive care unit for treatment of (CPA) community acquired pneumonia. Treating with have imaging, labs, and treating with antibiotics, serial vital signs
Patient had severe soreness and pain for almost a month. Couldn't move his arm for the first 3 days.
At 4:30 AM the day after the vaccine, I woke up with severe chills and shivering that my teeth were chattering. My body temp is naturally a degree higher than most people. I keep a jacket on in the winter, but it rarely is zipped up. I tried to drink warm tea. When that didn't work, I took a warm shower. I threw up 3 moderate to large emesis during the warm shower, then 2 small to medium-sized emesis. I felt like I went through rigorous physical training; I was that weak. My body ached crazy for the whole day. I lost a day of school because of it. I am sick literally, maybe once or twice a year at most.
pt recv vax 12MAY97 & 5min later exp dizziness;24hr p/vax exp a rash, flat, w/no itch, on chest & back; rash treated w/DPH ointment & resolved;
This spontaneous report was received from a registered pharmacist refers to female patient of approximately 68 years of age. On 28-MAY-2013, the patient was vaccinated with a dose of ZOSTAVAX (lot # reported as J00494). On an unknown date in 2013, the patient had experienced redness and swelling at the injection site after receiving ZOSTAVAX. The outcome of redness and swelling at the injection site was reported as recovered. This is 1 of 2 reports received from the same reporter. Additional information has been requested.